Tandem Diabetes (TNDM) Misses Q3 EPS by 28c, Revenues Beat; Offers FY18 Revenue Outlook Above Consensus

Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.62), $0.28 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $46.26 million versus the consensus estimate of $41.83 million.

“We delivered a record-setting quarter in terms of robust sales, improving gross margin and modest use of cash,” said Kim Blickenstaff, president and chief executive officer. “We’ll be working to build upon this momentum by continuing to scale our business into a leading global diabetes management organization, while advancing our product pipeline and furthering our mission to improve the lives of people with diabetes.”

GUIDANCE:

Tandem Diabetes sees FY2018 revenue of $160-165 million, versus the consensus of $155.42 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Hermès can regain momentum despite China weakness, Jefferies says
• MP Materials seen largely insulated after China export-control move